Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature

被引:300
作者
Cai, Weibo [1 ,2 ]
Chen, Kai [1 ,2 ]
Li, Zi-Bo [1 ,2 ]
Gambhir, Sanjiv S. [1 ,2 ,3 ]
Chen, Xiaoyuan [1 ,2 ]
机构
[1] Stanford Univ, Sch Med, Dept Radiol, Mol Imaging Program Stanford MIPS, Stanford, CA 94305 USA
[2] Stanford Univ, Sch Med, Bio X Program, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Bioengn, Stanford, CA 94305 USA
关键词
dual-function probe; PET; near-infrared fluorescence; quantum dot; integrin alpha(v)beta(3);
D O I
10.2967/jnumed.107.043216
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
To date, the in vivo imaging of quantum dots (QDs) has been mostly qualitative or semiquantitative. The development of a dual-function PET/near-infrared fluorescence (NIRF) probe can allow for accurate assessment of the pharmacokinetics and tumor-targeting efficacy of QDs. Methods: A QD with an amine-functionalized surface was modified with RGD peptides and 1,4,7,10-tetraazacyclodocecane-N,N',N '',N'"-tetraacetic acid (DOTA) chelators for integrin alpha(v)beta(3)-targeted PET/NIRF imaging. A cell-binding assay and fluorescence cell staining were performed with U87MG human glioblastoma cells (integrin alpha(v)beta(3)-positive). PET/NIRF imaging, tissue homogenate fluorescence measurement, and immunofluorescence staining were performed with U87MG tumor-bearing mice to quantify the probe uptake in the tumor and major organs. Results: There are about 90 RGD peptides per QD particle, and DOTA-QD-RGD exhibited integrin (alpha(v)beta(3)-Specific binding in cell cultures. The U87MG tumor uptake of Cu-64-labeled DOTA-QD was less than 1 percentage injected dose per gram (%ID/g), significantly lower than that of Cu-64-labeled DOTA-QD-RGD (2.2 +/- 0.3 [mean +/- SD] and 4.0 +/- 1.0 %ID/g at 5 and 18 h after injection, respectively; n = 3). Taking into account all measurements, the liver-, spleen-, and kidney-to-muscle ratios for 64Cu-labeled DOTA-QD-RGD were about 100: 1, 40:1, and 1:1, respectively. On the basis of the PET results, the U87MG tumor-to-muscle ratios for DOTA-QD-RGD and DOTA-QD were about 4:1 and 1: 1, respectively. Excellent linear correlation was obtained between the results measured by in vivo PET imaging and those measured by ex vivo NIRF imaging and tissue homogenate fluorescence (r(2) = 0.93). Histologic examination revealed that DOTA-QD-RGD targets primarily the tumor vasculature through an RGD-integrin alpha(v)beta(3) interaction, with little extravasation. Conclusion: We quantitatively evaluated the tumor-targeting efficacy of a dual-function OD-based probe with PET and NIRF imaging. This dual-function probe has significantly reduced potential toxicity and overcomes the tissue penetration limitation of optical imaging, allowing for quantitative targeted imaging in deep tissue.
引用
收藏
页码:1862 / 1870
页数:9
相关论文
共 39 条
  • [1] Nanocrystal targeting in vivo
    Åkerman, ME
    Chan, WCW
    Laakkonen, P
    Bhatia, SN
    Ruoslahti, E
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (20) : 12617 - 12621
  • [2] Noninvasive imaging of quantum dots in mice
    Ballou, B
    Lagerholm, BC
    Ernst, LA
    Bruchez, MP
    Waggoner, AS
    [J]. BIOCONJUGATE CHEMISTRY, 2004, 15 (01) : 79 - 86
  • [3] Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects
    Cai, WB
    Shin, DW
    Chen, K
    Gheysens, O
    Cao, QZ
    Wang, SX
    Gambhir, SS
    Chen, XY
    [J]. NANO LETTERS, 2006, 6 (04) : 669 - 676
  • [4] Are quantum dots ready for in vivo imaging in human subjects?
    Cai, Weibo
    Hsu, Andrew R.
    Li, Zi-Bo
    Chen, Xiaoyuan
    [J]. NANOSCALE RESEARCH LETTERS, 2007, 2 (06): : 265 - 281
  • [5] Cai WB, 2007, J NUCL MED, V48, P304
  • [6] Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression
    Cai, Weibo
    Chen, Xiaoyuan
    [J]. FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 4267 - 4279
  • [7] How molecular imaging is speeding up antiangiogenic drug development
    Cai, Weibo
    Rao, Jianghong
    Gambhir, Sanjiv S.
    Chen, Xiaoyuan
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (11) : 2624 - 2633
  • [8] In vitro and in vivo characterization of 64Cu-labeled Abegrin™ a humanized monoclonal antibody against integrin αvβ3
    Cai, Weibo
    Wu, Yun
    Chen, Kai
    Cao, Qizhen
    Tice, David A.
    Chen, Xiaoyuan
    [J]. CANCER RESEARCH, 2006, 66 (19) : 9673 - 9681
  • [9] Cai WB, 2006, J NUCL MED, V47, P2048
  • [10] Cai Weibo, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P407, DOI 10.2174/187152006778226530